Total Payments
$646,650
2023 Payments
$3,157
Companies
14
Transactions
831
Payment Breakdown by Category
Other$439,477 (68.0%)
Consulting$96,570 (14.9%)
Travel$96,184 (14.9%)
Food & Beverage$14,410 (2.2%)
Education$9.54 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $439,477 | 167 | 68.0% |
| Consulting Fee | $96,570 | 33 | 14.9% |
| Travel and Lodging | $96,184 | 356 | 14.9% |
| Food and Beverage | $14,410 | 273 | 2.2% |
| Education | $9.54 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $248,843 | 277 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $194,041 | 320 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $101,509 | 96 | $0 (2022) |
| Mylan Specialty L.P. | $61,276 | 108 | $0 (2021) |
| Mylan Inc. | $14,000 | 2 | $0 (2021) |
| F. Hoffmann-La Roche AG | $8,243 | 6 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $4,131 | 4 | $0 (2018) |
| GlaxoSmithKline, LLC. | $3,633 | 2 | $0 (2020) |
| Boehringer Ingelheim International GmbH | $3,324 | 2 | $0 (2021) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $3,220 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $3,157 | 6 | Merck Sharp & Dohme LLC ($2,900) |
| 2022 | $455.64 | 5 | Boehringer Ingelheim Pharmaceuticals, Inc. ($290.00) |
| 2021 | $9,886 | 6 | Mylan Inc. ($5,250) |
| 2020 | $50,454 | 47 | Mylan Specialty L.P. ($25,530) |
| 2019 | $61,827 | 90 | Mylan Specialty L.P. ($25,686) |
| 2018 | $218,941 | 283 | AstraZeneca Pharmaceuticals LP ($120,734) |
| 2017 | $301,928 | 394 | AstraZeneca Pharmaceuticals LP ($112,760) |
All Payment Transactions
831 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $59.07 | General |
| Category: Immunology | ||||||
| 09/21/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 06/26/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| 05/21/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $37.97 | General |
| Category: Immunology | ||||||
| 05/08/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $67.18 | General |
| Category: Immunology | ||||||
| 02/02/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $93.15 | General |
| Category: Immunology | ||||||
| 09/29/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $55.04 | General |
| Category: Immunology | ||||||
| 05/16/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $145.00 | General |
| Category: RESPIRATORY | ||||||
| 05/15/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $145.00 | General |
| Category: RESPIRATORY | ||||||
| 05/15/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $40.22 | General |
| Category: Immunology | ||||||
| 02/15/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $70.38 | General |
| Category: Immunology | ||||||
| 10/12/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPIRIVA (Drug) | Consulting Fee | Cash or cash equivalent | $1,545.00 | General |
| Category: RESPIRATORY | ||||||
| 09/08/2021 | Mylan Specialty L.P. | YUPELRI (Drug) | Consulting Fee | Cash or cash equivalent | $399.75 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 08/03/2021 | Boehringer Ingelheim International GmbH | STIOLTO RESPIMAT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $563.65 | General |
| Category: RESPIRATORY | ||||||
| 04/14/2021 | Mylan Specialty L.P. | YUPELRI (Drug) | Consulting Fee | Cash or cash equivalent | $1,064.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 04/09/2021 | Mylan Specialty L.P. | YUPELRI (Drug) | Consulting Fee | Cash or cash equivalent | $1,064.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 03/18/2021 | Mylan Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $5,250.00 | General |
| 12/18/2020 | Mylan Specialty L.P. | Yupelri (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,064.00 | General |
| Category: Respiratory and Allergy | ||||||
| 12/02/2020 | Mylan Specialty L.P. | Yupelri (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,064.00 | General |
| Category: Respiratory and Allergy | ||||||
| 12/02/2020 | Mylan Specialty L.P. | Yupelri (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,064.00 | General |
| Category: Respiratory and Allergy | ||||||
| 08/20/2020 | Mylan Specialty L.P. | Yupelri (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,330.00 | General |
| Category: Respiratory and Allergy | ||||||
| 06/02/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $7,968.16 | General |
| Category: RESPIRATORY | ||||||
| 04/23/2020 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| Category: RESPIRATORY | ||||||
| 04/09/2020 | Mylan Specialty L.P. | Yupelri (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,596.00 | General |
| Category: Respiratory and Allergy | ||||||
| 04/09/2020 | Mylan Specialty L.P. | Yupelri (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $665.00 | General |
| Category: Respiratory and Allergy | ||||||
About Dr. Donald Tashkin, MD
Dr. Donald Tashkin, MD is a Pulmonary Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528088135.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Donald Tashkin, MD has received a total of $646,650 in payments from pharmaceutical and medical device companies, with $3,157 received in 2023. These payments were reported across 831 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($439,477).
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Los Angeles, CA
- Active Since 07/20/2006
- Last Updated 07/22/2010
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1528088135
Products in Payments
- UTIBRON (Drug) $124,872
- BEVESPI AEROSPHERE (Drug) $118,656
- SYMBICORT (Drug) $89,880
- LONHALA MAGNAIR (Drug) $55,334
- Yupelri (Drug) $51,216
- FASENRA (Drug) $20,439
- OFEV (Drug) $18,425
- STIOLTO RESPIMAT (Drug) $10,347
- Wixela Inhub (Drug) $8,750
- Actemra (Biological) $8,243
- BROVANA (Drug) $6,250
- STIOLTO (Drug) $5,980
- Utibron (Drug) $4,542
- DUPIXENT DUPILUMAB INJECTION (Biological) $4,131
- NUCALA (Biological) $3,250
- YUPELRI (Drug) $2,528
- SPIRIVA (Drug) $2,495
- DUPIXENT (Biological) $423.01
- ANORO (Drug) $383.00
- Prolastin-C (Biological) $125.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Los Angeles
Prof. Toby Maher, Md, MD
Pulmonary Disease — Payments: $1.1M
Pulmonary Disease $1.1M
Rajan Saggar, Md, MD
Pulmonary Disease — Payments: $426,392
Pulmonary Disease $426,392
John Belperio, Md, MD
Pulmonary Disease — Payments: $308,808
Pulmonary Disease $308,808
Christopher Cooper, Md, MD
Pulmonary Disease — Payments: $207,817
Pulmonary Disease $207,817
Robert Strieter, Md, MD
Pulmonary Disease — Payments: $172,942
Pulmonary Disease $172,942
Roy Artal, M.d, M.D
Pulmonary Disease — Payments: $151,187
Pulmonary Disease $151,187